• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Adaptive Biotechnologies (ADPT) Stock Looks Fully Valued Following Its Huge Three Year Run

    Simply Wall St·10/25/2026 12:23:36
    語音播報

    Adaptive Biotechnologies has seen its share price move sharply in recent years, which naturally raises a question for anyone looking at the stock today. Are the cash flows that Adaptive Biotechnologies can realistically generate enough to support the current market value implied by that run up?

    • Over the past 3 years the share price has delivered a very large gain, so a lot of future cash flow is now effectively being brought forward into today's valuation.
    • The business relies heavily on turning its core immune system mapping platform into recurring revenue, which can directly shape how quickly cash flows scale and how much reinvestment is needed along the way.
    • Prefer to judge Adaptive Biotechnologies on sales? See why Adaptive Biotechnologies's 13.2x P/S tells a different valuation story.

    The issue now is whether the current price of Adaptive Biotechnologies is well supported by the cash flows suggested by its intrinsic value estimate using a Discounted Cash Flow model.

    If you want a broader sense of how other businesses compare when you think about cash flows versus market price, you can look at Adaptive Biotechnologies alongside 29 high quality undervalued stocks.

    Is Adaptive Biotechnologies Fairly Priced on Cash Flow?

    The Discounted Cash Flow (DCF) framework here is built around what Adaptive Biotechnologies might earn for shareholders over time rather than just today’s story. The latest twelve month free cash flow shows a cash outflow of about $26.7 million, so the model leans heavily on a shift toward positive and rising cash generation in the coming years.

    Analysts and internal estimates in this 2 Stage Free Cash Flow to Equity model project Adaptive Biotechnologies moving from that recent cash burn to steadily higher annual free cash flow in $ millions, then settling into slower expansion beyond the early ramp up period. When those projected streams are discounted back and compared with the current share price of $25.51, the DCF output suggests the estimated intrinsic value sits broadly in line with where the market is pricing the stock today. Find out what Adaptive Biotechnologies could be worth using our Discounted Cash Flow (DCF) estimate.

    The Adaptive Biotechnologies Narrative: What Would Justify Today's Price?

    Narratives on Simply Wall St pick up where the Adaptive Biotechnologies valuation puzzle leaves off by spelling out which paths for growth, margins and earnings would need to play out for the shares to end up worth meaningfully more or less than today’s price on a Community page built for that purpose. Each narrative treats Adaptive Biotechnologies' estimated worth as a clear thesis about the business that you can track over time rather than a one off snapshot.

    Community views on Adaptive Biotechnologies are split between MRD momentum supporting more upside and insider selling hinting that plenty of good news is already reflected.

    Bull case: 14% undervalued

    "Marked improvement in profitability, with the MRD segment now EBITDA positive and company-wide cash burn improving 36% year-over-year, signals the business reaching scale..."

    Discover why this Narrative puts Adaptive Biotechnologies at 14% undervalued.

    Bear case: 21% overvalued

    "Although Adaptive Biotechnologies reports strong MRD revenue of US$66.2 million in Q2 2026 with higher clinical volumes and rising sequencing gross margin, large 2026 insider and institutional share sales risk signaling internal caution..."

    Explore why this Narrative puts Adaptive Biotechnologies at 21% overvalued.

    Before acting on Adaptive Biotechnologies' valuation, weigh who is steering the ship

    Cash flow projections only tell part of the story, since the people setting priorities and the way they are rewarded can heavily shape long term outcomes for Adaptive Biotechnologies. See who runs Adaptive Biotechnologies and how they are paid.